More misery in Portugal as companies brace for post bailout fallout
This article was originally published in Scrip
Pharma companies in Portugal could see an already tough operating environment worsen in light of an imminent EU bailout. Industry commentators say the coming months could see a shortfall of funding for biotech ventures, company bankruptcies and a heightened perception of Portugal's geographic risk. There could also be more price cuts, which could have wider consequences for company revenues elsewhere thanks to reference pricing.